期刊
CURRENT OPINION IN HIV AND AIDS
卷 8, 期 3, 页码 230-235出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/COH.0b013e32835ef089
关键词
HIV; immune response; latency; resting CD4(+) T cells
资金
- National Institutes of Health [AI082608, MH085597, DA030156, R00046, AI50410]
Purpose of review A serious effort has begun to develop therapies that may be capable of eradicating established HIV infection in man. Because of the biological complexity of HIV infection that persists despite potent antiretroviral therapy, it is widely believed that if such therapies can be developed they will involve complex, multimodality approaches. We highlight some of the recent studies in this effort. Recent findings An inhibitor of histone deacetylase has been demonstrated to disrupt latency in man, and new histone deacetylase inhibitors have been identified. Other potential targets, such as histone methyltransferase, protein kinase C, and BRD4, have been recently studied. Model systems, both in primary cells and in animal models, are beginning to be validated. In the clinic, immune-based therapies to aid in the clearance of persistent infection are also being tested. Summary It is too early to know what combination eradication therapies for HIV infection will look like in the future, but candidate therapies and model systems to perform preclinical validation are beginning to take shape.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据